of intravenous rituximab (375 mg/m2 on days 3, 10, 17, and 24) . The primary endpoint was EFS in the intent-to-treat population, and safety was assessed in all participants
Positive Phase 2 Clinical Results of LAG-3 Therapy for Non-Small Cell Lung Cancer
Time of Update: 2022-04-22
"References:[1] Immutep's efti in combination with MSD's pembrolizumab shows encouraging antitumor activity in difficult to treat 2nd line metastatic lung cancer patients.
Target Oncol: Real-world exploration of the efficacy of Crizotinib in patients with ROS1-positive advanced non-small cell lung cancer (NSCLC)
Time of Update: 2022-03-04
Therefore, a team from the United States conducted a relevant real-world study to evaluate the efficacy of Crizotinib (crizotinib) in patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) .
Molecular mechanism of bacterial effector proteins antagonizing host antibacterial autophagy and a general mechanism of cell-selective autophagy
Time of Update: 2022-02-20
, the team of Shao Feng from the Beijing Institute of Biological Sciences revealed the molecular mechanism of heterophagy for the first time . After bacteria invade the host cell, the V-ATPase
cell differentiation in patients with antinuclear antibody-positive juvenile idiopathic arthritis
Time of Update: 2022-02-18
Conclusions: Clonally expanded CD4+ Tph cells accumulate in the joints of ANA -positive JIA patients, especially promoting CD21 low/ low/ – – CD11c+ DN B cell differentiation .
Clin Exp Immunol: Interferon-Gamma- and perforin-positive T cells in acquired aplastic anemia predict response to immunosuppressive therapy
Time of Update: 2022-01-23
of T lymphocytes in the bone marrow and destruction of hematopoietic stem cells by effector cells . Interferon
The latest data on allogeneic BCMA CAR-T therapy is positive, and "spot type" cell therapy can be expected in the future. Mai Meng broke the news
Time of Update: 2021-12-30
> ▲ The design of ALLO-715 (picture source: Allogene official website) As of October 14, 2021, a total of 48 patients were enrolled in the study, of which 43 patients were evaluable for safety and effectiveness, and 5 patients
Express 100% of patients get objective relief, and the latest clinical results of ready-to-use natural killer cell therapy are positive
Time of Update: 2021-12-05
▎Editor of WuXi AppTec Content Team On November 22, 2021, Affimed announced that its cord blood-derived natural killer cell therapy was pre-combined with the innate cell engager (ICE) AFM13.
TCR2 and Bristol-Myers Squibb form a partnership to evaluate mesothelin-positive solid tumor cell therapy
Time of Update: 2021-12-04
TCR2 Therapeutics recently announced that it has reached a clinical trial cooperation agreement with Bristol-Myers Squibb (BMS) and plans to launch a phase 2 clinical trial to evaluate a new
100% of patients get objective relief, and the latest clinical results of ready-to-use natural killer cell therapy are positive
Time of Update: 2021-12-01
On November 22, 2021, Affimed announced that its umbilical cord blood-derived natural killer cell therapy will be combined with the innate cell engager (ICE) AFM13 in advance to treat Hodgkins and patients who have received multi-line pre-treatment.
Stem cell therapy for Alzheimer's disease shows positive potential
Time of Update: 2021-11-15
In this study, scientists first successfully induced human iPSCs carrying the APOE3 gene to differentiate into GABAergic interneuron progenitor cells.
Nature Biotechnology: A new way to selectively turn on RNA therapy in human cells
Time of Update: 2021-11-15
Researchers have found a way to produce genetically modified genes only after "reading" specific RNA sequences in cells, thereby developing a technology that can fine-tune gene therapy, with applications ranging from regenerative medicine to cancer treatment .
Express treatment of Alzheimer's disease, stem cell therapy shows positive potential
Time of Update: 2021-11-15
▎Editor of WuXi AppTec's content team recently, GABAeron announced active preclinical research data obtained from cell therapy for Alzheimer's disease based on induced pluripotent stem cells (iPSC) .
Next-generation RNA therapy: a way to selectively turn on gene therapy in human cells
Time of Update: 2021-11-15
Their technology can detect specific messenger RNA sequences in cells, and then trigger transgenes or artificial genes to produce specific proteins .
The diversity of cells in the sponge sheds light on the evolution of the nervous system｜Science Weekly Selection
Time of Update: 2021-11-14
According to a new study, the specialized cells in the digestive chamber of the sponge (our furthest animal relative) may represent the starting point of the evolution of the nervous system .
